KRON News and Press, Kronos Bio Inc. From 08/17/23

SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, announced that its Chief Financial Officer and Head of Corporate Development, Yasir Al-Wakeel, BM BCh, will resign ...

2023-08-08 17:56:37 ET Kronos Bio press release ( NASDAQ: KRON ): Q2 GAAP EPS of -$0.52 misses by $0.04 . Revenue of $1.86M beats by $0.61M . For further details see: Kronos Bio  GAAP EPS of -$0.52 misses by $0.04, revenue of $1.86M beats by $0.61M

Data from the Phase 1 dose escalation portion of the Phase 1/2 KB-0742 study will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2023 The Company recently opened the third dosing cohort in the escalation portion of t...

2023-07-11 17:08:02 ET Gainers: Incyte  ( NASDAQ: INCY ) +4% . Veracyte ( VCYT ) +4% . Kronos ( KRON ) +3% . Applied Optoelectronics  ( AAOI ) +3% . GoodRx  ( GDRX ) +3% . Losers: Silk Road  ( SI...

2023-07-06 10:07:55 ET Gainers: CytoMed Therapeutics Limited ( GDTC ) +7% . Kronos Bio ( KRON ) +11% . Incannex Healthcare Limited ( IXHL ) +6% . Palatin Technologies ( PTN ) +6% . Losers: VBI Vaccines VBIV -55% . Allarity Th...

SAN MATERO, Calif. and CAMBRIDGE, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Marc Besman Ph.D., as Senior Vice President of Regulatory Affairs and Clinical ...

2023-05-10 17:49:08 ET Kronos Bio press release ( NASDAQ: KRON ): Q1 GAAP EPS of -$0.46 misses by $0.02 . Revenue of $1.22M misses by $3.78M . Cash, Cash Equivalents and Investments: With its ongoing and currently planned clinical programs and $241.3 million in...

Enrollment ongoing in expansion portion of Phase 1/2 KB-0742 study, with initial efficacy data expected in 2H 2023 Phase 1b/2 study of lanraplenib in combination with gilteritinib in FLT3-mutated AML on track to report recommended Phase 2 dose and initial data in Q4 2023 or Q1 2024 ...

SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Roger Dansey, M.D., to the company’s Board of Directors. Dr. Dansey brin...

Katherine Vega Stultz appointed to Board Current Board member Otello Stampacchia, Ph.D., stepped down SAN MATEO, Calif. and CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by canc...